Information Provided By:
Fly News Breaks for October 18, 2019
DVAX
Oct 18, 2019 | 07:06 EDT
H.C. Wainwright analyst Edward White initiated coverage of Dynavax Technologies with a Buy rating and $13 price target. The analyst sees sales growth of the company's marketed hepatitis B vaccine, Heplisav-B. About 5.5M doses of hepatitis B vaccines are given in the U.S. annually, and that number will rise due to the increasing number of people at risk for the disease and awareness of the disease, White tells investors in a research note. He points out that Heplisav-B is the first and only hepatitis B vaccine that is administered as two doses.